655 related articles for article (PubMed ID: 17909064)
1. Enhancement of antibody-dependent mechanisms of tumor cell lysis by a targeted activator of complement.
Imai M; Ohta R; Varela JC; Song H; Tomlinson S
Cancer Res; 2007 Oct; 67(19):9535-41. PubMed ID: 17909064
[TBL] [Abstract][Full Text] [Related]
2. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.
Stavenhagen JB; Gorlatov S; Tuaillon N; Rankin CT; Li H; Burke S; Huang L; Vijh S; Johnson S; Bonvini E; Koenig S
Cancer Res; 2007 Sep; 67(18):8882-90. PubMed ID: 17875730
[TBL] [Abstract][Full Text] [Related]
3. Potentiation of tumor lysis by a bispecific antibody that binds to CA19-9 antigen and the Fc gamma receptor expressed by human large granular lymphocytes.
de Palazzo IG; Gercel-Taylor C; Kitson J; Weiner LM
Cancer Res; 1990 Nov; 50(22):7123-8. PubMed ID: 2146012
[TBL] [Abstract][Full Text] [Related]
4. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16.
Weiner LM; Holmes M; Adams GP; LaCreta F; Watts P; Garcia de Palazzo I
Cancer Res; 1993 Jan; 53(1):94-100. PubMed ID: 8093231
[TBL] [Abstract][Full Text] [Related]
5. Evidence for an important interaction between a complement-derived CD21 ligand on follicular dendritic cells and CD21 on B cells in the initiation of IgG responses.
Qin D; Wu J; Carroll MC; Burton GF; Szakal AK; Tew JG
J Immunol; 1998 Nov; 161(9):4549-54. PubMed ID: 9794381
[TBL] [Abstract][Full Text] [Related]
6. Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells.
Hong F; Hansen RD; Yan J; Allendorf DJ; Baran JT; Ostroff GR; Ross GD
Cancer Res; 2003 Dec; 63(24):9023-31. PubMed ID: 14695221
[TBL] [Abstract][Full Text] [Related]
7. CR2 is a complement activator and the covalent binding site for C3 during alternative pathway activation by Raji cells.
Mold C; Nemerow GR; Bradt BM; Cooper NR
J Immunol; 1988 Mar; 140(6):1923-9. PubMed ID: 2831273
[TBL] [Abstract][Full Text] [Related]
8. Human complement receptor type 2 (CR2/CD21) transgenic mice provide an in vivo model to study immunoregulatory effects of receptor antagonists.
Kulik L; Chen K; Huber BT; Holers VM
Mol Immunol; 2011 Mar; 48(6-7):883-94. PubMed ID: 21269698
[TBL] [Abstract][Full Text] [Related]
9. Extended flexible linker structures in the complement chimaeric conjugate CR2-Ig by scattering, analytical ultracentrifugation and constrained modelling: implications for function and therapy.
Gilbert HE; Aslam M; Guthridge JM; Holers VM; Perkins SJ
J Mol Biol; 2006 Feb; 356(2):397-412. PubMed ID: 16375923
[TBL] [Abstract][Full Text] [Related]
10. Human K/natural killer cells targeted with hetero-cross-linked antibodies specifically lyse tumor cells in vitro and prevent tumor growth in vivo.
Titus JA; Perez P; Kaubisch A; Garrido MA; Segal DM
J Immunol; 1987 Nov; 139(9):3153-8. PubMed ID: 2959724
[TBL] [Abstract][Full Text] [Related]
11. Granulocyte-colony stimulating factor enhances chimeric antibody Nd2 dependent cytotoxicity against pancreatic cancer mediated by polymorphonuclear neutrophils.
Tamamori Y; Sawada T; Nishihara T; Yamashita Y; Ohira M; Ho JJ; Kim YS; Hirakawa-Y S Chung K
Int J Oncol; 2002 Sep; 21(3):649-54. PubMed ID: 12168113
[TBL] [Abstract][Full Text] [Related]
12. Modulation of the humoral immune response by antibody-mediated antigen targeting to complement receptors and Fc receptors.
Baiu DC; Prechl J; Tchorbanov A; Molina HD; Erdei A; Sulica A; Capel PJ; Hazenbos WL
J Immunol; 1999 Mar; 162(6):3125-30. PubMed ID: 10092761
[TBL] [Abstract][Full Text] [Related]
13. Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors.
Gillies SD; Lan Y; Lo KM; Super M; Wesolowski J
Cancer Res; 1999 May; 59(9):2159-66. PubMed ID: 10232603
[TBL] [Abstract][Full Text] [Related]
14. Low doses of antigen coupled to anti-CR2 mAbs induce rapid and enduring IgG immune responses in mice and in cynomolgus monkeys.
Whipple EC; Ditto AH; Shanahan RS; Gatesman JJ; Little SF; Taylor RP; Lindorfer MA
Mol Immunol; 2007 Jan; 44(4):377-88. PubMed ID: 16631928
[TBL] [Abstract][Full Text] [Related]
15. Activation of B cells in vivo by a Fab/Fc fragment of a monoclonal anti-IgD antibody requires an interaction between the antibody fragment and a cellular IgG Fc receptor.
Goroff DK; Finkelman FD
J Immunol; 1988 May; 140(9):2919-24. PubMed ID: 2966202
[TBL] [Abstract][Full Text] [Related]
16. A novel mechanism of alternative pathway complement activation accounts for the deposition of C3 fragments on CR2-expressing homologous cells.
Schwendinger MG; Spruth M; Schoch J; Dierich MP; Prodinger WM
J Immunol; 1997 Jun; 158(11):5455-63. PubMed ID: 9164968
[TBL] [Abstract][Full Text] [Related]
17. Human monocyte-mediated cytotoxicity: the use of Ig-bearing hybridomas as target cells to detect trigger molecules on the monocyte cell surface.
Graziano RF; Fanger MW
J Immunol; 1987 Feb; 138(3):945-50. PubMed ID: 2949010
[TBL] [Abstract][Full Text] [Related]
18. Development of a novel bi-specific monoclonal antibody approach for tumour targeting.
Koumarianou AA; Hudson M; Williams R; Epenetos AA; Stamp GW
Br J Cancer; 1999 Oct; 81(3):431-9. PubMed ID: 10507767
[TBL] [Abstract][Full Text] [Related]
19. Binding activities and antitumor properties of a new mouse/human chimeric antibody specific for GD2 ganglioside antigen.
Alvarez-Rueda N; Leprieur S; Clémenceau B; Supiot S; Sébille-Rivain V; Faivre-Chauvet A; Davodeau F; Paris F; Barbet J; Aubry J; Birklé S
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5613s-5620s. PubMed ID: 17875797
[TBL] [Abstract][Full Text] [Related]
20. The production and preclinical characterization of a chimeric anti-breast-cancer antibody, cBC2.
Sutton VR; Burgess J; Pietersz GA; Li WJ; McKenzie IF; Trapani JA
Ther Immunol; 1994 Apr; 1(2):83-93. PubMed ID: 7584487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
